Engineering lactate-modulating nanomedicines for cancer therapy.
暂无分享,去创建一个
[1] Pan‐Chyr Yang,et al. An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy , 2022, Nano Today.
[2] Yannan Yang,et al. A Sub-6 nm MnFe2O4-dichloroacetic acid nanocomposite modulates tumor metabolism and catabolism for reversing tumor immunosuppressive microenvironment and boosting immunotherapy. , 2022, Biomaterials.
[3] Juan Li,et al. Localized NIR-II laser mediated chemodynamic therapy of glioblastoma , 2022, Nano Today.
[4] M. Mazurczak,et al. Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma , 2022, Investigational New Drugs.
[5] Heliang Yao,et al. Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity , 2022, Nano Today.
[6] J. Ren,et al. Yeast@MOF bioreactor as a tumor metabolic symbiosis disruptor for the potent inhibition of metabolically heterogeneous tumors , 2022, Nano Today.
[7] Shiying Li,et al. Self-Delivery Ternary Bioregulators for Photodynamic Amplified Immunotherapy by Tumor Microenvironment Reprogramming. , 2022, ACS nano.
[8] Bingjun Sun,et al. Synergetic lethal energy depletion initiated by cancer cell membrane camouflaged nano-inhibitor for cancer therapy , 2022, Nano Research.
[9] He Lian,et al. Zinc-enriched nanosystem for dual glycolysis regulation and photothermal therapy to synergistically inhibit primary melanoma and lung metastasis , 2022, Chemical Engineering Journal.
[10] Wei-Hai Chen,et al. A Self-Driven Bioreactor Based on Bacterium-Metal-Organic Framework Biohybrids for Boosting Chemotherapy via Cyclic Lactate Catabolism. , 2021, ACS nano.
[11] H. Khan,et al. Targeting lactate metabolism and glycolytic pathways in the tumor microenvironment by natural products: A promising strategy in combating cancer , 2021, BioFactors.
[12] Mo Yang,et al. Dual‐Depletion of Intratumoral Lactate and ATP with Radicals Generation for Cascade Metabolic‐Chemodynamic Therapy , 2021, Advanced science.
[13] Lisi Xie,et al. Metal-Phenolic Network-Enabled Lactic Acid Consumption Reverses Immunosuppressive Tumor Microenvironment for Sonodynamic Therapy. , 2021, ACS nano.
[14] Zhijie Jiang,et al. Bi-directional nanosystem breaking tumor microenvironment and vessels induced negative Möbius ring. , 2021, Journal of controlled release : official journal of the Controlled Release Society.
[15] Pei Zhang,et al. Lactate in the tumour microenvironment: From immune modulation to therapy , 2021, EBioMedicine.
[16] Yan Yang,et al. Nanofactory for metabolic and chemodynamic therapy: pro-tumor lactate trapping and anti-tumor ROS transition , 2021, Journal of Nanobiotechnology.
[17] Yan Hu,et al. Activatable Biomineralized Nanoplatform Remodels the Intracellular Environment of Multidrug-Resistant Tumors for Enhanced Ferroptosis/Apoptosis Therapy. , 2021, Small.
[18] Qigang Wang,et al. Peroxisome inspired hybrid enzyme nanogels for chemodynamic and photodynamic therapy , 2021, Nature Communications.
[19] Leilei Tian,et al. Advanced Cancer Starvation Therapy by Simultaneous Deprivation of Lactate and Glucose Using a MOF Nanoplatform , 2021, Advanced science.
[20] Pan‐Chyr Yang,et al. Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer. , 2021, Drug discovery today.
[21] Yu Wang,et al. Lactate Consumption via Cascaded Enzymes Combined VEGF siRNA for Synergistic Anti‐Proliferation and Anti‐Angiogenesis Therapy of Tumors , 2021, Advanced healthcare materials.
[22] D. Haas-Kogan,et al. Harnessing Lactate Metabolism for Radiosensitization , 2021, Frontiers in Oncology.
[23] Qi Wang,et al. Zwitterion-based hydrogen sulfide nanomotors induce multiple acidosis in tumor cells by destroying tumor metabolic symbiosis. , 2021, Angewandte Chemie.
[24] Masaki Kobayashi,et al. Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4). , 2021, Pharmacology & therapeutics.
[25] Guanbin Song,et al. Tumor-Targeted Disruption of Lactate Transport with Reactivity-Reversible Nanocatalysts to Amplify Oxidative Damage. , 2021, Small.
[26] F. Jiang,et al. Recent Advances in Nanomaterial‐Based Nanoplatforms for Chemodynamic Cancer Therapy , 2021, Advanced Functional Materials.
[27] M. Bruchez,et al. Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer , 2021, Advanced materials.
[28] R. Basaraba,et al. Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review , 2021, Frontiers in Cellular and Infection Microbiology.
[29] Xiaobing Zhang,et al. An Acidity-Unlocked Nanoplatform Enables Self-Boosting ROS Generation through Upregulation of Lactate for Highly Specific Chemodynamic Therapy. , 2021, Angewandte Chemie.
[30] J. Rothstein,et al. Metabolic support of tumor-infiltrating regulatory T cells by lactic acid , 2020, Nature.
[31] C. Donohoe,et al. The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment. , 2020, Cancer letters.
[32] Dongkai Wang,et al. Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment. , 2020, ACS applied materials & interfaces.
[33] A. Yamauchi,et al. Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice , 2020, Cellular and molecular gastroenterology and hepatology.
[34] K. Cai,et al. Engineering of Cascade-Responsive Nanoplatform to Inhibit Lactate Efflux for Enhanced Tumor Chemo-Immunotherapy. , 2020, ACS nano.
[35] A. Griffioen,et al. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[36] Ping-Chih Ho,et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments , 2020, Nature Reviews Immunology.
[37] Si-Xue Cheng,et al. Intervening Tumor Progression by Coupling Bacteria Respiration with Tumor Metabolism. , 2020, Angewandte Chemie.
[38] S. Dhar,et al. Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration. , 2020, ACS nano.
[39] Shumin Li,et al. Openwork@Dendritic Mesoporous Silica Nanoparticles for Lactate Depletion and Tumor Microenvironment Regulation. , 2020, Angewandte Chemie.
[40] Xiaoyan Zhang,et al. Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism , 2020, Journal of Nanobiotechnology.
[41] Samir Mitragotri,et al. Physical triggering strategies for drug delivery. , 2020, Advanced drug delivery reviews.
[42] Hyesun Hyun,et al. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment , 2020, Acta Pharmacologica Sinica.
[43] Zhijie Jiang,et al. Jet‐Lagged Nanoparticles Enhanced Immunotherapy Efficiency through Synergistic Reconstruction of Tumor Microenvironment and Normalized Tumor Vasculature , 2020, Advanced healthcare materials.
[44] V. Ganapathy,et al. The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment , 2020, Oncogene.
[45] R. Mahato,et al. Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment , 2020 .
[46] Yufang Zhu,et al. Porphyrin‐Based Metal–Organic Frameworks for Biomedical Applications , 2020, Angewandte Chemie.
[47] W. Bu,et al. Amorphous Fe‐Based Nanoagents for Self‐Enhanced Chemodynamic Therapy by Re‐Establishing Tumor Acidosis , 2019, Advanced Functional Materials.
[48] Yi Zhang,et al. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment , 2019, Journal of Hematology & Oncology.
[49] Mei‐Zhen Zou,et al. Intra/Extracellular Lactic Acid Exhaustion for Synergistic Metabolic Therapy and Immunotherapy of Tumors , 2019, Advanced materials.
[50] J. Manzo-Merino,et al. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches , 2019, Front. Oncol..
[51] Y. Qu,et al. Catalytically Selective Chemotherapy from Tumor-Metabolic Generated Lactic Acid. , 2019, Small.
[52] Xuesi Chen,et al. Advances in nanomedicine for cancer starvation therapy , 2019, Theranostics.
[53] Yucai Wang,et al. Near-Infrared II Phototherapy Induces Deep Tissue Immunogenic Cell Death and Potentiates Cancer Immunotherapy. , 2019, ACS nano.
[54] Qiu-Yun Chen,et al. The NIR inspired nano-CuSMn(II) composites for lactate and glycolysis attenuation. , 2019, Colloids and surfaces. B, Biointerfaces.
[55] Zhuang Liu,et al. Hollow Cu2Se Nanozymes for Tumor Photothermal-Catalytic Therapy , 2019, Chemistry of Materials.
[56] Pierre Sonveaux,et al. Monocarboxylate transporters in cancer , 2019, Molecular metabolism.
[57] Yu Chen,et al. Nanocatalytic Medicine , 2019, Advanced materials.
[58] K. Kataoka,et al. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment. , 2019, Accounts of chemical research.
[59] Kyung Soo Park,et al. Cancer nanomedicine for combination cancer immunotherapy , 2019, Nature Reviews Materials.
[60] R. Gillies,et al. Causes, consequences, and therapy of tumors acidosis , 2019, Cancer and Metastasis Reviews.
[61] Huarong Liu,et al. Tumor Reoxygenation and Blood Perfusion Enhanced Photodynamic Therapy using Ultrathin Graphdiyne Oxide Nanosheets. , 2019, Nano letters.
[62] Yifeng Zhang,et al. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice , 2019, Nature Communications.
[63] Yu Chen,et al. Nanocatalysts-augmented Fenton chemical reaction for nanocatalytic tumor therapy. , 2019, Biomaterials.
[64] Yu Chen,et al. Reactive Oxygen Species (ROS)-Based Nanomedicine. , 2019, Chemical reviews.
[65] Qin Xu,et al. Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. , 2019, Nano letters.
[66] Yucai Wang,et al. Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. , 2019, Nano letters.
[67] Ning Wang,et al. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment , 2019, Molecular Cancer.
[68] E. Giannoni,et al. Lactate: A Metabolic Driver in the Tumour Landscape. , 2019, Trends in biochemical sciences.
[69] Heliang Yao,et al. Nanocatalytic Tumor Therapy by Biomimetic Dual Inorganic Nanozyme‐Catalyzed Cascade Reaction , 2018, Advanced science.
[70] M. Morris,et al. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells , 2019, The AAPS Journal.
[71] H. Lane,et al. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells , 2018, Cell reports.
[72] Dirk Mossmann,et al. mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.
[73] Xiaofei Li,et al. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy , 2018, Cancer medicine.
[74] Pan‐Chyr Yang,et al. Targeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy. , 2018, ACS nano.
[75] F. Alam,et al. Lactate biosensing: The emerging point-of-care and personal health monitoring. , 2018, Biosensors & bioelectronics.
[76] E. Giannoni,et al. Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. , 2018, Cell metabolism.
[77] Yu Chen,et al. Gas‐Generating Nanoplatforms: Material Chemistry, Multifunctionality, and Gas Therapy , 2018, Advanced materials.
[78] Shibo Wang,et al. Interfering with Lactate‐Fueled Respiration for Enhanced Photodynamic Tumor Therapy by a Porphyrinic MOF Nanoplatform , 2018, Advanced Functional Materials.
[79] Jian Yu,et al. Immunogenic effects of chemotherapy-induced tumor cell death , 2018, Genes & diseases.
[80] P. Schreiner,et al. Computational Chemistry: The Fate of Current Methods and Future Challenges. , 2018, Angewandte Chemie.
[81] Qiu-Yun Chen,et al. An aptamer-Fe3+ modified nanoparticle for lactate oxidation and tumor photodynamic therapy. , 2018, Colloids and surfaces. B, Biointerfaces.
[82] O. Feron,et al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects , 2018, Nature Communications.
[83] Yuzhuo Wang,et al. Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. , 2018, Angewandte Chemie.
[84] J. Pouysségur,et al. Disrupting the 'Warburg effect' re-routes cancer cells to OXPHOS offering a vulnerability point via 'ferroptosis'-induced cell death. , 2017, Advances in biological regulation.
[85] J. Guan,et al. Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity , 2017, Science Immunology.
[86] Joshua D. Rabinowitz,et al. Glucose feeds the TCA cycle via circulating lactate , 2017, Nature.
[87] Xiaoyuan Chen,et al. Nanotechnology for Multimodal Synergistic Cancer Therapy. , 2017, Chemical reviews.
[88] Weijian Chen,et al. Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy. , 2017, Nano letters.
[89] Jianlin Shi,et al. Tumor-selective catalytic nanomedicine by nanocatalyst delivery , 2017, Nature Communications.
[90] D. Wallace,et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. , 2017, Cell metabolism.
[91] S. Halford,et al. A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. , 2017 .
[92] Liangzhu Feng,et al. H2O2-responsive liposomal nanoprobe for photoacoustic inflammation imaging and tumor theranostics via in vivo chromogenic assay , 2017, Proceedings of the National Academy of Sciences.
[93] W. Wagner,et al. Stimulation of lactate receptor (HCAR1) affects cellular DNA repair capacity. , 2017, DNA repair.
[94] P. Kantoff,et al. Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.
[95] Pierre Sonveaux,et al. Monocarboxylate transporters in the brain and in cancer☆ , 2016, Biochimica et biophysica acta.
[96] S. Horvath,et al. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. , 2016, Cell reports.
[97] P. Zhu,et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells , 2016, Oncotarget.
[98] M. Moyer,et al. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. , 2015, Cancer letters.
[99] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[100] W. Zhan,et al. Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: involvement of the Akt-mTOR signaling pathway. , 2015, Cancer letters.
[101] S. Weinberg,et al. Targeting mitochondria metabolism for cancer therapy. , 2015, Nature chemical biology.
[102] E. Golden,et al. Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.
[103] Jun Hu,et al. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. , 2014, Cancer letters.
[104] F. Sotgia,et al. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. , 2014, Seminars in cancer biology.
[105] Yuanzhong Wu,et al. Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway. , 2014, Cancer letters.
[106] Matthew G. Vander Heiden,et al. Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.
[107] Z. Husain,et al. Tumor-derived lactate and myeloid-derived suppressor cells , 2013, Oncoimmunology.
[108] Z. Huang,et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.
[109] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[110] E. Rajnavölgyi,et al. Dendritic Cell Reprogramming by Endogenously Produced Lactic Acid , 2013, The Journal of Immunology.
[111] M. Nitti,et al. Role of Glutathione in Cancer Progression and Chemoresistance , 2013, Oxidative medicine and cellular longevity.
[112] E. Michelakis,et al. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology , 2013, Front. Oncol..
[113] J. Schlesselman,et al. A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.
[114] M. Vettraino,et al. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[115] Richard A Flavell,et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.
[116] Bin Hu,et al. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activation , 2012, International journal of cancer.
[117] E. White. Deconvoluting the context-dependent role for autophagy in cancer , 2012, Nature Reviews Cancer.
[118] R. Jain,et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.
[119] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[120] R. Hamanaka,et al. Targeting glucose metabolism for cancer therapy , 2012, The Journal of experimental medicine.
[121] M. Recanatini,et al. Galloflavin (CAS 568‐80‐9): A Novel Inhibitor of Lactate Dehydrogenase , 2012, ChemMedChem.
[122] O. Feron,et al. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments , 2011, Disease Models & Mechanisms.
[123] W. Wilson,et al. Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.
[124] E. Giovannetti,et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. , 2011, Journal of medicinal chemistry.
[125] W. Denny. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. , 2010, Future oncology.
[126] Amanda S Barnard,et al. One-to-one comparison of sunscreen efficacy, aesthetics and potential nanotoxicity. , 2010, Nature nanotechnology.
[127] G. Semenza. HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.
[128] G. Semenza,et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.
[129] P. Carmeliet,et al. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. , 2010, Genes & cancer.
[130] A. Barnard. How can ab initio simulations address risks in nanotech? , 2009, Nature nanotechnology.
[131] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[132] Anthony Mancuso,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.
[133] M.-H. Lee,et al. Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer , 2008, Cellular and Molecular Life Sciences.
[134] R. Deberardinis,et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.
[135] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[136] C. Thompson,et al. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. , 2007, Cancer cell.
[137] R. I. Viji,et al. Endothelial cell response to lactate: Implication of PAR modification of VEGF , 2007, Journal of cellular physiology.
[138] R. Cardone,et al. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis , 2005, Nature Reviews Cancer.
[139] A. Barclay,et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression , 2000, The EMBO journal.
[140] A. Halestrap,et al. Inhibition and labelling of the erythrocyte lactate transporter by stilbene disulphonates. , 1990, Biochemical Society transactions.
[141] R. Denton,et al. The specificity and metabolic implications of the inhibition of pyruvate transport in isolated mitochondria and intact tissue preparations by alpha-Cyano-4-hydroxycinnamate and related compounds. , 1975, The Biochemical journal.
[142] O. Warburg,et al. THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.